Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 142 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2014', provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bile Duct Cancer (Cholangiocarcinoma) Overview 9
Therapeutics Development 10
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 10
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 11
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 12
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 15
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 18
Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 19
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 20
Sanofi 20
AstraZeneca PLC 21
Eli Lilly and Company 22
GlaxoSmithKline plc 23
Plexxikon Inc. 24
Panacea Pharmaceuticals, Inc. 25
Novartis AG 26
Exelixis, Inc. 27
Celgene Corporation 28
Bayer AG 29
Access Pharmaceuticals, Inc. 30
OncoTherapy Science, Inc. 31
PCI Biotech AS 32
Provecs Medical GmbH 33
Agios Pharmaceuticals, Inc. 34
Boston Biomedical, Inc. 35
Merrimack Pharmaceuticals, Inc. 36
Cornerstone Pharmaceuticals, Inc. 37
NuCana BioMed Limited 38
Arrien Pharmaceuticals, LLC 39
Senhwa Biosciences, Inc. 40
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
regorafenib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
vandetanib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AP-5346 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
trametinib dimethyl sulfoxide - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
paclitaxel albumin bound - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
cabozantinib s-malate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
elpamotide - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
BGJ-398 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
LY-2801653 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
BBI-503 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CPI-613 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
binimetinib - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
silmitasertib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
gemcitabine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PLX-8394 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
SAR-408701 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
seribantumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
NUC-1031 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
AG-120 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Im-01 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
PAN-622 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
ARN-5032 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
JP-1584 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 97
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 134
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 135
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 136
Featured News & Press Releases 136
Jul 15, 2014: CellAct Pharma Receives Orphan Drug Designation in EU for CAP7.1 in Biliary Tract Cancers 136
Jun 17, 2014: Senhwa Biosciences Initiates Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin 136
Mar 12, 2014: Cornerstone Pharmaceuticals Lead Compound CPI-613 Demonstrates Ability to Disrupt Growth of Cancer Cells 137
Apr 10, 2013: Lilly Reveals Data Of LY2801653 At AACR Annual Meeting 138
Aug 14, 2012: Provecs Medical Receives US Patent Covering Technology Around Immunalon 139
Jan 10, 2012: Clinical Study Confirms Benitec's Gene-silencing Technology Is Safe And Effective In Fang Vaccine 139
Apr 07, 2009: Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II REOLYSIN and Radiation Combination Clinical Trial For The Trial REO 008 140
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 142
Disclaimer 142

List of Tables
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2014 10
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H2 2014 20
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca PLC, H2 2014 21
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H2 2014 22
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by GlaxoSmithKline plc, H2 2014 23
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Plexxikon Inc., H2 2014 24
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H2 2014 25
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H2 2014 26
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H2 2014 27
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H2 2014 28
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2014 29
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Access Pharmaceuticals, Inc., H2 2014 30
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H2 2014 31
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech AS, H2 2014 32
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H2 2014 33
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H2 2014 34
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H2 2014 35
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 36
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 37
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H2 2014 38
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 39
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences, Inc., H2 2014 40
Assessment by Monotherapy Products, H2 2014 41
Number of Products by Stage and Target, H2 2014 44
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H2 2014 97
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H2 2014 134
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H2 2014 135